Share This Page
Suppliers and packagers for generic pharmaceutical drug: amlodipine besylate; telmisartan
✉ Email this page to a colleague
amlodipine besylate; telmisartan
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Alembic | TELMISARTAN AND AMLODIPINE | amlodipine besylate; telmisartan | TABLET;ORAL | 205234 | ANDA | Alembic Pharmaceuticals Limited | 46708-184-08 | 80 BLISTER PACK in 1 CARTON (46708-184-08) / 8 TABLET in 1 BLISTER PACK | 2016-11-22 |
| Alembic | TELMISARTAN AND AMLODIPINE | amlodipine besylate; telmisartan | TABLET;ORAL | 205234 | ANDA | Alembic Pharmaceuticals Limited | 46708-185-08 | 80 BLISTER PACK in 1 CARTON (46708-185-08) / 8 TABLET in 1 BLISTER PACK | 2016-11-22 |
| Alembic | TELMISARTAN AND AMLODIPINE | amlodipine besylate; telmisartan | TABLET;ORAL | 205234 | ANDA | Alembic Pharmaceuticals Limited | 46708-186-06 | 60 BLISTER PACK in 1 CARTON (46708-186-06) / 6 TABLET in 1 BLISTER PACK | 2016-11-22 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
AMLODIPINE BESYLATE; TELMISARTAN API Suppliers and Market Landscape
This analysis identifies key suppliers of Active Pharmaceutical Ingredients (APIs) for Amlodipine Besylate and Telmisartan, examines their manufacturing capabilities, and outlines the current market dynamics influencing their operations. The focus is on companies with established production capacity and a documented history of supplying these critical cardiovascular drug components.
Who are the Primary API Suppliers for Amlodipine Besylate?
Several manufacturers globally produce Amlodipine Besylate API. Key players include those with significant chemical synthesis expertise and regulatory compliance.
- India: The Indian pharmaceutical industry is a dominant force in API manufacturing. Companies like Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, and Divi's Laboratories are significant producers. Dr. Reddy's Laboratories has a long-standing presence in cardiovascular APIs, including Amlodipine Besylate, with multiple manufacturing sites adhering to cGMP standards. Sun Pharmaceutical Industries, through its extensive API division, also contributes to global supply chains for this compound. Divi's Laboratories is known for its large-scale contract manufacturing and its own portfolio of high-volume APIs, frequently including Amlodipine Besylate.
- China: Chinese manufacturers represent another substantial segment of the global API market. Companies such as Lupin (with manufacturing operations in China) and independent entities like Zhejiang NHU Co., Ltd. are involved. Zhejiang NHU Co., Ltd. is a large chemical enterprise with a dedicated pharmaceutical segment that produces a range of APIs, including Amlodipine Besylate.
- Europe: While production is more concentrated in Asia, some European companies may offer niche or specialized grades. However, large-volume production is less common compared to India and China.
Table 1: Select Amlodipine Besylate API Manufacturers
| Manufacturer | Country of Origin | Key Strengths |
|---|---|---|
| Dr. Reddy's Laboratories | India | cGMP compliance, extensive R&D, established supply chain |
| Sun Pharmaceutical Industries | India | Broad API portfolio, global distribution |
| Divi's Laboratories | India | Large-scale production, contract manufacturing |
| Zhejiang NHU Co., Ltd. | China | Chemical synthesis expertise, diverse product range |
| Lupin | India (with China ops) | Integrated manufacturing, regulatory adherence |
What are the Key API Suppliers for Telmisartan?
Telmisartan, an angiotensin II receptor blocker, is also manufactured by a concentrated group of global API producers, predominantly in India and China, mirroring the trend for Amlodipine Besylate.
- India: Indian companies are leading suppliers. Hetero Drugs, Aurobindo Pharma, and Natco Pharma are prominent. Hetero Drugs operates multiple cGMP-compliant API manufacturing facilities and has a strong presence in generics, including cardiovascular drugs. Aurobindo Pharma is vertically integrated, with significant API production capacity across various therapeutic areas. Natco Pharma focuses on niche and complex generics, often including APIs for blockbuster drugs.
- China: Chinese manufacturers play a crucial role. Lupin (again, with manufacturing facilities in China) and companies like Zhejiang Huahai Pharmaceutical Co., Ltd. are significant. Zhejiang Huahai Pharmaceutical Co., Ltd. is a well-established API and finished dosage form producer with a strong export market, recognized for its production of Sartans.
- Other Regions: Limited production may exist in other regions, but the volume and cost-competitiveness are typically dominated by Asian manufacturers.
Table 2: Select Telmisartan API Manufacturers
| Manufacturer | Country of Origin | Key Strengths |
|---|---|---|
| Hetero Drugs | India | cGMP facilities, large-scale production |
| Aurobindo Pharma | India | Vertical integration, broad API portfolio |
| Natco Pharma | India | Complex generics, specialized APIs |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | China | Sartan expertise, strong export compliance |
| Lupin | India (with China ops) | Integrated supply chain, global regulatory filings |
What are the Manufacturing Capabilities and Regulatory Status of these Suppliers?
Suppliers for both Amlodipine Besylate and Telmisartan must adhere to stringent regulatory standards to supply regulated markets like the U.S. and Europe.
- cGMP Compliance: All major API manufacturers supplying to the U.S. FDA, European Medicines Agency (EMA), and other stringent regulatory authorities (SRAs) must operate under current Good Manufacturing Practices (cGMP). This includes robust quality management systems, validated processes, and detailed documentation. Inspections by these agencies are routine.
- DMF Filings: Manufacturers typically file Drug Master Files (DMFs) with regulatory agencies. A U.S. DMF provides confidential detailed information about facilities, processes, or articles, allowing the FDA to review proprietary information while protecting its confidentiality. Similar filings exist in Europe (ASMF/EDMF).
- Capacity and Scale: Companies like Divi's Laboratories and Zhejiang Huahai are known for their massive production scales, capable of supplying significant global demand. This often translates to cost advantages.
- Quality Control: Advanced analytical laboratories are essential for ensuring API purity, potency, and the absence of impurities. Stability testing under various conditions (ICH guidelines) is also a critical aspect.
- Supply Chain Robustness: Manufacturers are increasingly evaluated on their supply chain resilience, including raw material sourcing and risk mitigation strategies, particularly in light of geopolitical and environmental disruptions.
Table 3: Regulatory Approvals and Certifications
| Manufacturer | U.S. FDA Approval Status (Representative) | EMA Approval Status (Representative) | Other Certifications (e.g., WHO-GMP) |
|---|---|---|---|
| Dr. Reddy's Laboratories | Active DMFs, successful inspections | Active ASMFs, site approvals | ISO, OHSAS |
| Sun Pharmaceutical Industries | Active DMFs, regular inspections | Active ASMFs, inspections | ISO, environmental certs |
| Divi's Laboratories | Multiple active DMFs, strong inspection record | Multiple active ASMFs, site approvals | ISO, safety standards |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | Numerous active DMFs, consistent approvals | Numerous active ASMFs, strong audit history | ISO, Responsible Care |
| Hetero Drugs | Multiple active DMFs, established history | Multiple active ASMFs, regulatory approvals | ISO, environmental management |
What are the Market Drivers and Challenges for these APIs?
The market for Amlodipine Besylate and Telmisartan APIs is influenced by several factors.
- Growing Prevalence of Cardiovascular Diseases: The increasing global incidence of hypertension and heart disease directly drives demand for antihypertensive medications, thus boosting API requirements.
- Generic Competition: Both Amlodipine Besylate and Telmisartan are off-patent. This leads to significant price pressure on generic drug manufacturers, which in turn puts pressure on API suppliers to maintain competitive pricing.
- Consolidation in the Pharmaceutical Industry: Mergers and acquisitions among generic drug companies can alter procurement volumes and supplier relationships.
- Regulatory Scrutiny: Increased regulatory oversight, particularly concerning impurities (e.g., nitrosamines in Sartans), leads to higher compliance costs and the need for enhanced analytical capabilities and process control. Suppliers must demonstrate robust control over potential genotoxic impurities.
- Geopolitical Factors and Supply Chain Risks: Dependence on specific regions for API production creates vulnerabilities. Trade tensions, environmental regulations, and global health crises can disrupt supply chains. This is leading some pharmaceutical companies to diversify their supplier base.
- Intellectual Property Landscape: While the primary patents have expired, there can still be secondary patents related to polymorphs, formulations, or manufacturing processes that can influence market entry for some players.
Key Trends:
- Vertical Integration: API manufacturers are increasingly seeking to integrate forward into finished dosage forms, and conversely, finished drug manufacturers are exploring backward integration into API production to secure supply and control costs.
- Focus on Impurity Control: Regulatory bodies are demanding tighter control over impurities, especially genotoxic ones. This necessitates significant investment in analytical technology and process chemistry expertise.
- Sustainability and Environmental, Social, and Governance (ESG) Factors: Pharmaceutical companies are increasingly scrutinizing their suppliers' ESG performance. API manufacturers are being pushed to adopt more sustainable manufacturing practices and ensure ethical labor conditions.
- Technological Advancements: Continuous manufacturing and advanced process analytical technologies (PAT) are being explored to improve efficiency, quality, and reduce waste in API production.
Key Takeaways
- The global supply of Amlodipine Besylate and Telmisartan APIs is primarily concentrated among manufacturers in India and China, known for their large-scale production and cost competitiveness.
- Key suppliers like Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Divi's Laboratories, Hetero Drugs, Aurobindo Pharma, and Zhejiang Huahai Pharmaceutical Co., Ltd. operate under stringent cGMP regulations and maintain extensive regulatory filings (DMFs, ASMFs) with global health authorities.
- Market drivers include the rising prevalence of cardiovascular diseases, while significant challenges stem from intense generic competition, price pressures, and heightened regulatory scrutiny, particularly regarding impurity profiles.
- The industry is witnessing a trend towards increased focus on supply chain resilience, advanced impurity control, and ESG considerations from both suppliers and buyers.
Frequently Asked Questions
1. Which countries are the largest exporters of Amlodipine Besylate and Telmisartan APIs?
India and China are the largest exporters of Amlodipine Besylate and Telmisartan APIs globally, due to their established chemical manufacturing infrastructure and cost advantages.
2. What is the typical lead time for securing large quantities of these APIs?
Lead times for large quantities of APIs can range from 3 to 9 months, depending on the supplier's current production schedule, raw material availability, and the quantity ordered.
3. How do regulatory inspections impact API pricing?
Successful regulatory inspections (e.g., FDA, EMA) are critical for market access. While inspections themselves do not directly increase API price, the investment required to maintain cGMP compliance, validated processes, and robust quality systems is factored into the overall cost of production and thus the API price. Non-compliance can lead to costly remediation, product recalls, and market withdrawal, impacting supply and potentially increasing prices for available compliant batches.
4. What are the primary concerns regarding impurities in Telmisartan APIs?
A significant concern for Telmisartan APIs, and other Sartans, is the potential presence of nitrosamine impurities, such as N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA). Regulatory agencies require stringent testing and control strategies to ensure these impurities are below acceptable daily intake limits.
5. How does a supplier's financial stability influence API procurement decisions?
A supplier's financial stability is crucial for ensuring long-term supply reliability. Companies facing financial distress may be at risk of production disruptions or, in extreme cases, cessation of operations. Pharmaceutical companies assess financial health through credit ratings, public financial reports, and discussions with supplier management to mitigate supply chain risk.
[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA website] (Actual URL would be specific to FDA DMF information if publicly accessible and relevant). [2] European Medicines Agency. (n.d.). Active Substance Master File (ASMF). Retrieved from [EMA website] (Actual URL would be specific to EMA ASMF information if publicly accessible and relevant). [3] World Health Organization. (n.d.). Good Manufacturing Practices. Retrieved from [WHO website] (Actual URL would be specific to WHO GMP guidelines if publicly accessible and relevant). [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH website] (Actual URL would be specific to ICH stability guidelines if publicly accessible and relevant).
More… ↓
